Skip to main content
. 2019 May 23;9(5):937–951. doi: 10.1016/j.apsb.2019.05.001

Figure 2.

Figure 2

Effect of HDAC isoform specific inhibitors on the cytotoxicity of ARS. (A) Cell viability of Hep3B cells treated with romidepsin (left), CI994 (middle) or tubastatin A (right) in combination with ARS. MTT assay were performed after 72 h treatment. Error bars represent SD of triplicate experiments. CI values are shown below the corresponding concentrations. (B) Romidepsin synergizes with ARS to inhibit A549 (left) and H1975 (right) cells. CI values were calculated as shown. (C) Representative microphotographs of Hep3B cells treated with ARS (20 μmol/L), romidepsin (5 nmol/L) and combination for 48 h (scale bars 40 μm). (D) Flow cytometric analysis of cell death of Hep3B cells treated with vehicle control, ARS (20 μmol/L), romidepsin (5 nmol/L) or the combination for 48 h by annexin V/PI assay.